Amantadine Hydrochloride Patent Expiration
Amantadine Hydrochloride is used for managing motor complications in patients with Parkinson's disease receiving levodopa-based therapy. It was first introduced by Endo Pharmaceuticals Inc
Amantadine Hydrochloride Patents
Given below is the list of patents protecting Amantadine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Gocovri | US11065213 | Amantadine compositions and preparations thereof | Aug 23, 2038 | Supernus Pharms |
Gocovri | US11077073 | Methods of using amantadine compositions | Aug 23, 2038 | Supernus Pharms |
Gocovri | US12233033 | Amantadine compositions, preparations thereof, and methods of use | Aug 23, 2038 | Supernus Pharms |
Osmolex Er | US10213393 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US10213394 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US10500170 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US10500171 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US10500172 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US10512617 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Osmolex Er | US11890261 | Composition and method for treating neurological disease | Feb 15, 2038 | Supernus Pharms |
Gocovri | US10154971 | Methods of administering amantadine | Dec 04, 2034 | Supernus Pharms |
Gocovri | US10646456 | Methods of administering amantadine | Jun 17, 2034 | Supernus Pharms |
Gocovri | US11903908 | Methods of administering amantadine | Jun 17, 2034 | Supernus Pharms |
Gocovri | US11197835 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Gocovri | US8741343 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Gocovri | US9867791 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Gocovri | US9867792 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Gocovri | US9867793 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Gocovri | US9877933 | Method of administering amantadine prior to a sleep period | Dec 02, 2030 | Supernus Pharms |
Osmolex Er | US8252331 | Osmotic device containing amantadine and an osmotic salt | Mar 13, 2030 | Supernus Pharms |
Gocovri | US8389578 | Composition and method for treating neurological disease | Jan 22, 2028 | Supernus Pharms |
Osmolex Er | US8389578 | Composition and method for treating neurological disease | Jan 22, 2028 | Supernus Pharms |
Osmolex Er | US8574626 | Osmotic device containing amantadine and an osmotic salt | Nov 28, 2025 | Supernus Pharms |
Gocovri | US8796337 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8889740 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8895614 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8895615 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8895616 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8895617 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Gocovri | US8895618 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8796337 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8889740 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8895614 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8895615 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8895616 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8895617 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8895618 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US8987333 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | US9072697 | Composition and method for treating neurological disease | Nov 23, 2025 | Supernus Pharms |
Osmolex Er | USRE39069 | Multi-layered osmotic device |
May 29, 2018
(Expired) | Supernus Pharms |
Amantadine Hydrochloride's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List